Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01999569
Other study ID # LH-2013
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 2007
Est. completion date May 2008

Study information

Verified date October 2021
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to establish that sustained estrogen levels are the driving force for the LH surge, and are thereby necessary for ovulation to occur. We predict that by reducing levels of circulating estrogen, letrozole, an aromatase inhibitor, will inhibit ovulation from occurring.


Description:

Sine the common understanding of ovulation in a natural cycle suggests that a sustained, elevated estradiol level is required to trigger the LH surge, administration of letrozole throughout the cycle should lower estradiol levels and prevent the LH surge from occurring. In this study, we sought to determine if the LH surge, ovulation and luteinization occurs in spite of low estradiol levels by daily administration of letrozole in a group of normal ovulatory volunteers in a prospective study. After IRB approval and informed consent were obtained, ten willing volunteers that met inclusion criteria (no hormonal contraception within 3 months, regular menstrual cycles 26 - 30 days, normal thyroid function and normal prolactin, and no pregnancy currently or within 3 months) were monitored for one month without treatment for evaluation of normal ovulation. Natural control cycle The subjects used home urine LH tests (Clearblue® Easy, SPD Swiss Precision Diagnostics, Switzerland) on days 10-18 to monitor for the LH surge in both the initial natural cycle and the letrozole cycle. Blood was drawn every other day starting on day 12 of the cycle through day 22 to measure estradiol and progesterone levels, and follicular development was monitored using transvaginal ultrasound on cycle day 12-14. Letrozole cycle In the next cycle, all ten subjects were administered oral letrozole 5 mg daily (Femara®, Novartis Pharmaceuticals Corporation, East Hanover, NJ ) starting on cycle day 1-3 and continuing through the completion of the study (cycle day 22). Once again, serum estradiol and progesterone levels were measured every other day on days 12-22. The development of the ovarian follicles was monitored by transvaginal ultrasound once in each cycle between days 12-14, and LH surge was monitored with home urine ovulation tests on days 10-18. Table 1 illustrates protocols for both the natural control cycle and the letrozole study cycle. The primary outcome, assessment of ovulation in letrozole cycles, was determined by the presence or absence of progesterone elevation (>1.5 ng/mL) and the presence or absence of a positive urinary LH test. The bioequivalence evaluation of two cycles (before and after letrozole administration) was based on pharmacokinetic parameters such as area under the serum concentration-time curve (AUC), the peak serum concentration (Cmax) and the time of peak serum concentration (Tmax). Cmax and Tmax were determined by visual inspection from each volunteer's serum concentration-time curve for estradiol and progesterone. AUC was calculated by the linear trapezoidal method from day 12 through day 22 in both the initial natural cycle and the letrozole cycle. Paired t-tests, or Wilcoxon Signed Rank tests if non-normally distributed, were used to evaluate the statistical significance of the mean values of the pharmacokinetic parameters. The McNemar test was used to assess the difference in LH surge and follicular development before and after letrozole administration. A standard of statistical significance (alpha) of 0.05 was used in all cases. The SAS System (SAS Institute, Cary, NC) was used for all analyses.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 2008
Est. primary completion date May 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Patient having regular menstrual cycles between 26-30 days - Ages 18-40 - Patient must not be sexually active during the study period, or if so must be using a reliable form of non-hormonal birth control including tubal ligation or vasectomy, non-hormonal intrauterine contraceptive device (IUD), or condoms with spermicide. - Willing to participate in study and available for all monitoring visits. - IRB consent Exclusion Criteria: - Patient must NOT have used hormonal contraception three months or less prior to study. - Irregular menstrual cycles (<26 days or >30 days within the last 6 months. - Untreated thyroid dysfunction or hyperprolactinemia - Pregnancy (current or within 3 months) or breastfeeding - Allergy or contraindication to letrozole

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Letrozole
Letrozole administered daily through the time of ovulation.

Locations

Country Name City State
United States Women's Institute at Carolinas Medical Center Charlotte North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

References & Publications (7)

Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010 Sep;6(5):243-6. doi: 10.1200/JOP.000082. Epub 2010 Aug 6. — View Citation

Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2006 Mar;91(3):760-71. Epub 2005 Dec 29. Review. — View Citation

Christensen A, Bentley GE, Cabrera R, Ortega HH, Perfito N, Wu TJ, Micevych P. Hormonal regulation of female reproduction. Horm Metab Res. 2012 Jul;44(8):587-91. doi: 10.1055/s-0032-1306301. Epub 2012 Mar 21. Review. — View Citation

Goh HH, Ratnam SS. The LH surge in humans: its mechanism and sex difference. Gynecol Endocrinol. 1988 Jun;2(2):165-82. Review. — View Citation

Laven JS, Fauser BC. What role of estrogens in ovarian stimulation. Maturitas. 2006 Jul 20;54(4):356-62. Epub 2006 Jun 19. Review. — View Citation

Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig. 2004 Sep;11(6):406-15. — View Citation

Morioka N, Zhu C, Brännström M, Woessner JF, LeMaire WJ. Mechanism of mammalian ovulation. Prog Clin Biol Res. 1989;294:65-85. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Progesterone Level Greater Than 1.5 ng/mL Serum progesterone ng/mL drawn during cycle days twelve through 22 Cycle days 12-22
Secondary Number of Participants With a Positive LH Test Urine ovulation tests assessed Cycle days 10-18
Secondary Number of Participants With Follicular Development Ovulation; elevated progesterone Cycle day 12
See also
  Status Clinical Trial Phase
Completed NCT02890914 - Transvaginal Ultrasound Training for Obstetrics and Gynecology Residents N/A
Completed NCT01779232 - Danazol Treatment in Endometriosis Women Before IVF Phase 4
Completed NCT05054946 - The Effect of Laparoscopic Surgery on Ovarian Reserve According to Cyst Types N/A
Completed NCT02852447 - The Effect of Surgery for Non Endometriosic Ovarian Cysts on Ovarian Reserve N/A
Completed NCT00713778 - The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst Phase 4
Suspended NCT00865488 - Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery Phase 3
Completed NCT04142203 - Implementation of 23 Hour Surgery Model in a Tertiary Hospital
Recruiting NCT05842629 - Improved Diagnosis of Ovarian Cancer
Completed NCT05376384 - Ovarian Cyst's Enucleation Spillage Score
Recruiting NCT04993924 - GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst Phase 4
Terminated NCT03189316 - Anti-inflammatory Cells in Peritoneal Cavity N/A
Completed NCT05800613 - Management of Ovarian Masses in Pediatric Patients: an Italian Survey
Completed NCT04355312 - Using INDOcyanine Green to Analyse Ovarian Vascularization After Ovarian Laparoscopic CYStectomy N/A
Completed NCT05418595 - Ultrasonographic Evaluation of Ovarian Stromal Vascularity in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT06342934 - Radiomics and Machine Learning in the Diagnosis of Ovarian Masses
Completed NCT06227676 - Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25 Phase 2/Phase 3
Recruiting NCT02831556 - Point of Care 3D Ultrasound for Various Applications: A Pilot Study
Recruiting NCT05763511 - Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
Completed NCT06064331 - Effect of Intravenous Lignocaine Infusion on Intraoperative End Tidal Desflurane Concentration Requirements N/A
Recruiting NCT02086318 - A New Algorithm to Predict Ovarian Age N/A